Efficacy and safety evaluation for 28 Chinese non-Hodgkin lymphoma patients treated with Hyper-CVAD/MA regimen

VernacularTitle:Hyper-CVAD/MA方案治疗28例中国人非霍奇金淋巴瘤的有效性及安全性
Author: Kaiyuan TENG ; Huiyan LUO ; Miaozhen QIU ; Fanghua LI ; Yanxia SHI ; Huiqiang HUANG ; Zhongjun XIA ; Wenqi JIANG ; Ruihua XU
Publication Type:Journal Article
Keywords: Lymphoma; non-Hodgkin; Antineoplastic combined chemotherapy protocols; Reproducibility of results
From: Cancer Research and Clinic 2009;21(10):660-662,665
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy and safety of the hyper-CVAD/MA regimen as an intensified treatment option for 28 T cell and aggressive/highly aggressive B cell NHL in Chinese patients. Methods Clinical data of 28 NHL patients treated with hyper-CVAD/MA regimen from Jan 2005 to Sep 2008 were retrospectively analyzed. Results 27 NHL patients were available for the efficacy analysis, with a response rate of 70.4 %. For the 13 B cell lymphoma cases, the response rate was 84.6 %. The main toxicity was Grade Ⅲ or Grade Ⅳ myelosuppression in all cases and 2 treatment related deaths. Conclusion Hyper-CVAD/MA regimen had a high response rate in T cell and aggressive /highly aggressive B cell NHL lymphoma, companied by significant toxicity when treating Chinese patients. Further clinical practices are needed to pick up a suitable dose which can balance efficacy and safety.